FGF13-AS1: A Promising Drug Target / Biomarker (G100129662)

Target Name: FGF13-AS1

NCBI ID: G100129662

FGF13-AS1

Other Name(s): FGF13 antisense RNA 1

FGF13-AS1: A Promising Drug Target / Biomarker

FGF13-AS1 is a protein that is expressed in various tissues throughout the body, including the skin, hair, nails, and bones. It is a member of the FGF family, which is known for their role in the development and maintenance of tissues. FGF13-AS1 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-Related Significance

FGF13-AS1 has been shown to be involved in several disease processes that are relevant to human health. One of the most significant roles of FGF13-AS1 is in the development and progression of cancer. FGF13-AS1 has been shown to promote the growth and survival of cancer cells, and it has been identified as a potential therapeutic target for cancer treatment.

FGF13-AS1 has also been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, and they are typically treated with a combination of therapeutic approaches that aim to slow down or reverse the progression of the disease. FGF13-AS1 has been shown to contribute to the development and progression of these conditions by promoting the growth and survival of neuroblast cells, which are a type of cell that are affected in neurodegenerative diseases.

FGF13-AS1 has also been shown to be involved in the development and progression of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These conditions are characterized by the immune system attacking the body's own tissues, and they are typically treated with a combination of immunosuppressive medications. FGF13-AS1 has been shown to contribute to the development and progression of these conditions by promoting the growth and survival of immune cells, which are a key part of the immune system.

Potential Therapeutic Applications

FGF13-AS1 has the potential to be a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the most promising approaches for targeting FGF13-AS1 is the use of small molecules, such as drugs that can modulate its activity.

One of the most promising small molecules that have been identified as potential FGF13-AS1 antagonists is a compound called FGF13-AS1 inhibitor-1 (FGF13-AS1-I1). This compound has been shown to inhibit the activity of FGF13-AS1 and prevent its ability to promote the growth and survival of cancer cells, neuroblast cells, and immune cells. FGF13-AS1-I1 has also been shown to be effective in animal models of cancer, including in the treatment of breast cancer.

Another small molecule that has been shown to be an FGF13-AS1 antagonist is a compound called FGF13-AS1 inhibitor-2 (FGF13-AS1-I2). This compound has been shown to inhibit the activity of FGF13-AS1 and prevent its ability to promote the growth and survival of cancer cells and immune cells. FGF13-AS1-I2 has also been shown to be effective in animal models of cancer, including in the treatment of lung cancer.

Another approach for targeting FGF13-AS1 is the use of antibodies, such as those that can bind to FGF13-AS1 and prevent it from functioning. One of the most promising antibodies that has been shown to be effective in this regard is an anti-FGF13-AS1 antibody, which has been shown to block

Protein Name: FGF13 Antisense RNA 1

The "FGF13-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FGF13-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets